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Abstract
Melanoma metastasis from an unknown primary cancer has an incidence of 3.2% among 
melanoma patients. Furthermore, paraneoplastic neurological syndromes (PNS) are rare, oc-
curring in 1–3% of patients with malignancies. Paraneoplastic cerebellar degeneration (PCD) 
is one of the classic PNS and is characterized by acute or subacute onset of ataxia and/or pres-
ence of onconeural antibodies. A 61-year-old male with ataxia, vertigo, and headache later 
developed dysarthria, multidirectional nystagmus, hyperactive delirium, auditory hallucina-
tions, psychomotor agitation, and myoclonus. Toxicological, metabolic, infectious, and auto-
immune etiologies were assessed and reported negative. An osteolytic lesion was observed 
in the right iliac crest via computed tomography (CT). A positron emission tomography-CT 
reported increased fluorodeoxyglucose uptake of a right iliac and right inguinal ganglion. Af-
ter biopsy of the right inguinal ganglion, a BRAF mutation-positive melanoma metastasis from 
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an occult primary cancer was diagnosed. Dermatologic, ophthalmologic, and endoscopic gas-
trointestinal assessment did not reveal a primary malignant melanoma. The patient’s move-
ment disorders and neuropsychiatric symptoms improved with quetiapine, prednisone, aza-
thioprine, and cyclophosphamide. Oncological management was conducted with MAPK 
pathway inhibitors (i.e., dabrafenib and trametinib). Movement disorders associated with neu-
ropsychiatric symptoms are complex to diagnose. PNS are rare and often associated with an-
tibodies against neural antigens expressed by the tumor. The case presented above describes 
a patient with a BRAF-positive malignant melanoma metastasis from an occult primary asso-
ciated with PCD – to the best of our knowledge, the first reported in the literature.
© 2020 The Author(s).
Published by S. Karger AG, Basel
Introduction
Ataxia is a disorder of balance and coordination involving dysfunctions of the cerebellum 
and its afferent and efferent connections [1]. Ataxia is usually an initial manifestation of cere-
bellar disease [2]. Among the etiologies that manifest with ataxia are: (1) cerebrovascular 
disease; (2) neoplasia and paraneoplastic diseases; (3) metabolic diseases (e.g., hypona-
tremia, hypoglycemia, and hyperazotemia); (4) pharmacologic or alcohol intoxication; (5) 
head trauma; (6) autoimmune disease (e.g., multiple sclerosis and acute disseminated enceph-
alomyelitis); (7) infectious disease (e.g., herpesvirus, HIV, and Epstein-Barr virus); and (8) 
polyradiculopathies (e.g., Miller Fisher syndrome and acute inflammatory demyelinating 
polyneuropathy) [2, 3].
Paraneoplastic neurological syndromes (PNS) occur in 1–3% of patients who have malig-
nancies [4]. Cerebellar ataxia is the movement disorder most commonly associated with PNS 
and is associated with several antibodies such as anti-Hu, anti-Ri, and anti-Yo [5]. Lymphoma, 
thymoma, and endometrial, breast, testicular and ovarian cancer have been associated with 
PNS characterized by cerebellar ataxia [6, 7]. Paraneoplastic cerebellar degeneration (PCD) 
is among the classic PNS (i.e., paraneoplastic limbic encephalitis, subacute sensory neuropathy, 
paraneoplastic opsoclonus-myoclonus, and Lambert-Eaton myasthenic syndrome) and is 
characterized by subacute development of pancerebellar dysfunction [8].
We present the case of a male patient with ataxia and PCD associated with a metastatic 
melanoma tumor. The patient had a sudden onset, developing behavioral and more movement 
disorders associated with the PNS. While infectious, toxicological, autoimmune, and meta-
bolic etiologies were excluded, a positive right inguinal ganglion biopsy revealed melanoma 
metastasis from an occult primary. This is the first case reported in the literature of PCD 
secondary to a BRAF-positive melanoma metastasis from an occult primary cancer and the 
second case of a PNS associated with a BRAF-mutant melanoma.
Clinical Presentation
A 61-year-old male arrived at the emergency department complaining of a headache with 
a frontal predominance that had progressively increased in 1 week to an 8/10 on the visual 
analog scale for pain at the time of admission. In the previous week, the patient reported an 
elevation in his blood pressure reaching 150/80 mm Hg. Meanwhile, the 24 h before seeking 
medical attention, the patient had had vertigo and ataxia without fever. The patient did not 
report any symptoms related to an acute infectious process (e.g., fever or malaise), nor alter-
ations in his sleep-wake cycle or seizures. The patient’s family history includes a mother with 
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thyroid and breast cancer under treatment and a brother with testicular cancer in remission, 
as well as hypertension under treatment. The patient had a personal history of hypertension 
and dyslipidemia treated for 15 years. The patient denied the use of controlled substances, 
allergies, past blood transfusions, traveling to regions with endemic diseases within the last 
3 months, tattoos, and body piercings.
Upon initial physical exploration, we found a recumbent patient with a freely chosen 
body position, a Glasgow Coma Scale score of 15 (i.e., eye-opening 4, verbal response 5, and 
motor response 6), without focal neurological deficits or meningeal signs, and aware of his 
environment. The patient’s integumentary system was hydrated and without alterations. The 
patient had bilateral horizontal nystagmus to the right, with isochoric pupils and the pupillary 
light reflex present. A fundus examination was not performed due to excessive saccadic eye 
movements. A musculoskeletal exploration revealed stereotyped movements in all four 
extremities. A cerebellar examination revealed bilateral dysdiadochokinesia and a negative 
Romberg test result, but no alterations in the finger-to-nose and heel-to-shin tests; no resting 
tremor was observed, and no reduction in muscle tone of the upper limbs, but gait was not 
assessed due to the severity of the ataxia. The patient had normal plantar and other deep 
tendon reflexes. Upon inspection, palpation, auscultation, and percussion, the cardiorespi-
ratory system had no abnormal findings. An abdominal examination yielded no alterations. 
Upon admission, the patient had the following vital signs: blood pressure of 200/100 mm Hg; 
a heart rate of 90 bpm; a respiratory rate of 18 breaths/min; a body temperature of 36.8°C; a 
body weight of 68.4 kg; a height of 172 cm; and a BMI of 22.2.
Fig. 1. Timeline of clinical presentation, clinical evolution, and clinical outcome. Summary of the clinical case 
with suspected diagnosis, laboratory and imaging workup, and management.
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Clinical Evolution
An emergency computed tomography (CT) of the brain was performed to assess intra-
axial lesions (e.g., hemorrhage, ischemia, and tumors), with normal findings. Management for 
the hypertensive urgency was initiated with antihypertensive drugs (Fig. 1). The patient was 
evaluated in the neurology department, initiating acyclovir and dexamethasone treatment, as 
a probable acute viral cerebellitis was suspected. A lumbar puncture was performed, yielding 
a cloudy aspect with mild pleocytosis (i.e., 20 cells/mm3), normal protein (i.e., 65.9 mg/dL) 
and glucose (i.e., 74.4 mg/dL) levels; a meningoencephalitis PCR assay was performed, with 
no reported bacterial, viral, or yeast infection (Table 1), and a CSF culture resulted negative. 
The laboratory results at admission and the thyroid function test results are presented in 
Table 1. To exclude systemic viral infection or drug use, the following tests were requested: 
antibodies against hepatitis B virus, hepatitis C virus, and HIV, as well as urinalysis for benzo-
diazepines, barbiturates, cannabis, cocaine, methamphetamines, and opiates; all results were 
Table 1. Laboratory test results upon admission
Full blood count Meningitis/encephalitis PCR assay
Hemoglobin at admission 15.0 g/dL Bacteria
Hematocrit 46.0% Escherichia coli K1 Not detected
Erythrocyte count 5,227/μL Haemophilus influenzae Not detected
Platelet count 378,000/μL Listeria monocytogenes Not detected
Mean corpuscular volume 91.5 fL Neisseria meningitides Not detected
Mean corpuscular hemoglobin 31.9 g/dL Streptococcus agalactiae Not detected
Leukocyte count 8,600/μL Streptococcus pneumoniae Not detected
Neutrophils 72.8% Mycobacterium tuberculosis Not detected
Lymphocytes 17.1% Viruses
Monocytes 8.3% Cytomegalovirus Not detected
Eosinophils 1.2% Enterovirus Not detected
Basophils 0.6% Herpes simplex virus 1 Not detected
Blood chemistry Herpes simplex virus 2 Not detected
Glucose 80 mg/dL Human herpesvirus 6 Not detected
Albumin 3.8 g/dL Human parechovirus Not detected
Urea nitrogen 24.0 mg/dL Varicella zoster virus Not detected
Blood urea nitrogen 47.0 mg/dL Yeast
Uric acid 4.8 mg/dL Cryptococcus neoformans/gattii Not detected
Cholesterol 130 mg/dL Cerebrospinal fluid
Triglycerides 110 mg/dL Aspect Rock water
Liver function enzymes Leukocytes 0
Aspartate transaminase 16.3 U/L Erythrocytes Scarce
Alanine transaminase 17.7 U/L Protein 65.9 mg/dL
Lactate dehydrogenase 230 U/L Glucose 74.4 mg/dL
Albumin 3.5 mg/dL Light India ink staining Negative
Alkaline phosphatase 50.8 U/L Gram staining No bacteria
Gamma-glutamyl transpeptidase 25 U/L Culture No development
Blood coagulation Thyroid function tests
Prothrombin time 15 s Serum thyroxine (T4) 9.16 μg/dL
Partial thromboplastin time 35 s Free thyroxine (fT4) 0.96 ng/dL
International normalized ratio 1.2 Serum triiodothyronine (T3) 0.7 ng/mL
Electrolytes T3 resin uptake (T3RU) 2.9 pg/mL
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reported as negative (Table 2). The procalcitonin serum level was 0.19 ng/mL and the lactate 
dehydrogenase level 230 U/L. Ancillary paraclinical tests were performed to assess systemic 
infection and an autoimmune etiology (Table 2). After an infectious etiology had been 
excluded, antiviral and antibiotic therapy were suspended.
After 5 days of hospitalization, the patient had a blood pressure of 160/100 mm Hg and 
his management was adjusted (Fig. 1). An electroencephalogram was also performed, yielding 
no epileptogenic or abnormal activity. On the sixth day of hospitalization, the patient developed 
dysarthria, multidirectional nystagmus, hyperactive delirium, auditory hallucinations, 
psychomotor agitation, and focal left shoulder myoclonus but no opsoclonus. Olanzapine, 
prednisone, azathioprine, and plasmapheresis management were initiated to treat the 
suspected autoimmune encephalitis (Fig. 1). In search of an autoimmune etiology, the 
following serum tests were requested: cytoplasmic antineutrophil cytoplasmatic antibodies 
(cANCA), perinuclear antineutrophil cytoplasmatic antibodies (pANCA), anti-double-
Table 2. Follow-up laboratory test results
Serum antibodies
Cytoplasmic antineutrophil cytoplasmatic antibodies (cANCA) 0.1
Perinuclear antineutrophil cytoplasmatic antibodies (pANCA) 0.2
Anti-nuclear antibodies 0.5 IU/mL
Anti-double-stranded deoxyribonucleic acid 1.94 IU/mL
Anti-cardiolipin IgG 3.0 IU/mL
Anti-cardiolipin IgM antibody 3.0 IU/mL
Anti-N-methyl-D-aspartate (NMDA), IgG receptor Negative





Hepatitis B virus Negative
Hepatitis C virus Negative
Human immunodeficiency virus Negative
Tumor markers
Alpha-fetoprotein 4.0 IU/mL
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stranded deoxyribonucleic acid, anti-cardiolipin IgG, anti-cardiolipin IgM antibody, and anti-
N-methyl-D-aspartate (NMDAR) IgG antibody; all were reported as negative (Table 2). The 
following tumor markers were screened, and all were reported negative: α-fetoprotein, 
human chorionic gonadotropin, CA125, CA153, CA19-9, and carcinoembryonic antigen 
(Table 2).
Clinical Outcome
In order to screen for a neoplastic process in the brain, simple and contrast MRI scans 
were performed, while simple and contrast thoracic, abdominal, and pelvic CT scans were 
also performed to noninvasively assess tumor presence or apparent lymphadenopathy. The 
brain MRI displayed reduced bilateral cortical volumes and an increased space bilaterally at 
the cerebellopontine angle (Fig. 2A–C); meanwhile, a 20 × 13 mm osteolytic lesion was 
observed in the right iliac crest in the pelvic portion of the whole-body CT (Fig. 2D). A testicular 
ultrasound (USG) was performed, but no solid mass was observed. To further explore the 
etiology of the PCD, the following serum onconeural biomarkers were assessed and reported 
negative: anti-Yo, anti-glutamic acid decarboxylase (GAD) 65, anti-Hu, and anti-Ri (Table 2). 
A positron emission tomography-CT was performed with fluorodeoxyglucose (18FDG), 
yielding cortical atrophy, a hypermetabolic thyroid nodule (i.e., 14 mm in diameter), a 20 × 
29 mm external right iliac nodule (Fig. 3) with an SUVmax of 19.4, and a right inguinal nodule 
with a 6-mm diameter and an SUVmax of 2.6. The patient continued having dysarthria, 
nystagmus, and ataxia; accordingly, the management was changed to quetiapine, prednisone, 
azathioprine, and cyclophosphamide (Fig. 1), with clinical improvement except for mild 
ataxia and dysarthria.
Percutaneous USG-guided biopsies of the inguinal ganglion (i.e., 32 × 17 mm by USG) and 
the thyroid nodule were performed. The thyroid biopsy resulted normal; meanwhile, the 
histological sections of the inguinal lymph node showed a poorly differentiated malignant 
neoplastic lesion constituted by pleomorphic cells and atypical large hyperchromic nuclei 
with prominent nucleoli (Fig. 4A). Immunohistochemical staining was performed, and anti-
bodies against HMB-45, melan-A, and S100 (Fig. 4B–D) were positive, while TTF1, CK20, and 
Fig. 2. Brain magnetic resonance 
imaging (MRI) and thoracic-ab-
dominopelvic computed tomog-
raphy (CT). A Axial T2-weighted 
MRI scan showing an increased 
subarachnoid space. B, C Coronal 
T2-weighted MRI scans showing 
reduced bilateral cortical vol-
umes, an increased space bilater-
ally at the cerebellopontine angle, 
and an increased subarachnoid 
space at the posterior cranial fos-
sa. D Coronal CT reconstruction 
with an osteolytic lesion (22 × 13 
mm) at the right iliac crest.
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CK7 antibody staining was negative. The integrated diagnosis was melanoma metastasis from 
an occult primary cancer (i.e., T0, N2b, M1c; clinical stage IV). The patient was assessed clin-
ically for neoplastic lesions at the dermatology and ophthalmology departments, without 
finding any primary tumors. In search of the primary melanoma site, colonoscopy and endo-
scopic assessment were performed, reporting no tumors. The oncology department requested 
PCR detection of the BRAF oncogene, with a positive result for V600E/Ec. Targeted therapy 
with selective inhibition of the MAPK pathway with dabrafenib and trametinib was initiated 
to treat the malignant melanoma metastasis.
Fig. 3. Whole-body positron 
emission tomography-computed 
tomography. A, B Coronal recon-
struction with an increased fluo-
rodeoxyglucose uptake (i.e., an 
SUVmax of 19.4) of a right iliac 
nodule (i.e., 20 × 29 mm) in the 
pelvic region. A right thyroid hy-
permetabolic nodule is also visi-
ble.
Fig. 4. Histopathology. A Inguinal 
lymph node ganglion, ×40, hema-
toxylin and eosin staining. There 
is a neoplasm composed of atypi-
cal dyscohesive cells that shows 
large and hyperchromatic nuclei, 
with pseudo-inclusions and eo-
sinophilic nucleoli. The cytoplasm 
is abundant and finely granular. 
B Immunohistochemistry, ×40, 
S100 staining. Strong and diffuse 
nuclear and cytoplasmic positivi-
ty for S100. C Immunohistochem-
istry, ×40, melan-A staining. 
Strong and diffuse cytoplasmic 
positivity for melan-A. D Immu-
nohistochemistry, ×40, HMB-45 
staining. Strong and diffuse cyto-
plasmic positivity but weak nu-
clear positivity for HMB-45.
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Discussion
To the best of our knowledge, this is the first case reported in the literature of a PNS with 
PCD secondary to a BRAF-positive malignant melanoma metastasis from an occult primary 
cancer. A melanoma metastasis from an unknown primary cancer is rare, with an incidence 
of 3.2% [9]. Furthermore, only 5 cases of PNS secondary to melanoma metastasis and only 1 
case involving a melanoma metastasis from an occult primary have previously been reported 
[10].
Our patient underwent whole-body CT, where an osteolytic lesion was observed; addi-
tionally, a positron emission tomography-CT with two positive ganglia (i.e., right iliac and 
inguinal) for FDG uptake were observed. The patient also had negative onconeural serum 
biomarkers (anti-Yo, anti-GAD 65, anti-Hu, and anti-Ri). After a biopsy of the ganglion, 
melanoma metastasis was diagnosed through immunohistochemistry. In search of the 
primary cancer site, the patient underwent endoscopic assessment of the entire gastroin-
testinal tract mucosa, as well as dermatologic and ophthalmologic clinical assessment, 
without yielding any tumors. After a positive result for the BRAF V600E/Ec oncogene, 
chemotherapy with dabrafenib and trametinib was initiated to treat the malignant 
melanoma metastasis.
PNS include PCD, paraneoplastic limbic encephalitis, subacute sensory neuropathy, para-
neoplastic opsoclonus-myoclonus, and Lambert-Eaton myasthenic syndrome [8]. Paraneo-
plastic degenerative cerebellar ataxia is defined as acute or subacute ataxia in a patient with 
cancer, diagnosed within 5 years, or with positive specific onconeural antibodies [11]. The 
association between PCD and malignant melanoma has previously been associated with 
carbonic anhydrase-related protein VIII [12]. A previous case of PCD revealed edema of the 
cerebellar cortex and a bilateral hyperintense signal at the caudate nuclei [13]. In the case 
presented here, the PCD was associated with an increased bilateral subarachnoid space at the 
pontocerebellar angle. PCD is characterized clinically by progressive ataxia associated with 
nausea and vertigo; meanwhile, this PNS has been linked to gynecological and breast carci-
nomas, small cell carcinoma of the lung, and Hodgkin’s disease [14]. Among the onconeural 
antibodies associated with PCD are anti-Yo, anti-Hu, anti-Ri, anti-mGluR1, anti-AMPA, anti-
GAD, and P/Q- and N-type calcium channel antibodies [14]. In the case presented here, the 
anti-Yo, anti-GAD 65, anti-Hu, and anti-Ri onconeural antibodies were negative. A case of a 
PNS associated with progressive ataxia and dysdiadochokinesia secondary to a BRAF-positive 
cutaneous malignant melanoma (note: also negative for onconeural antibodies) was treated 
with high-dose corticosteroids for symptomatic treatment and with dabrafenib and trametinib 
for the malignancy, with an adequate response [15].
Management of PNS centers on treatment of the underlying tumor and symptomatic 
treatment [8]. PCD rarely responds to immunotherapy and weakly to intravenous immuno-
globulin, steroids, or plasmapheresis [8]. Administration of intravenous rituximab or cyclo-
phosphamide pulses should be considered in refractory cases (i.e., no response or partial 
response) [5]. Our patient improved clinically after cyclophosphamide infusion (i.e., reduced 
ataxia and myoclonus). Treatment for the melanoma metastasis from an occult primary was 
with BRAF and MEK protein inhibitors (i.e., dabrafenib and trametinib).
Limitations
Other onconeural antibodies (e.g., voltage-gated calcium channel antibodies, anti-ANNA1, 
anti-ANNA2, anti-Tr, anti-amphiphysin, anti-Zic4, and anti-Purkinje cell antibody 2) could not 
be tested due to the out-of-pocket cost for the patient; furthermore, as the malignancy was 
immunohistochemically identified and was positive for BRAF oncogene mutation, our limited 
resources were allocated to the patient’s management and disease monitoring. An electromy-
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ography was not performed due to the patient’s refusal. Other treatments (e.g., intravenous 
immunoglobulin, plasma exchange, and rituximab) were not used initially to treat the PNS 
before the identification of the malignant melanoma.
Conclusions
This case is the first presenting with an occult primary BRAF-mutant malignant melanoma 
with PCD and the second case of a BRAF-mutant melanoma described in the literature. 
Movement disorders associated with neuropsychiatric symptoms are complex to diagnose. 
Infectious, metabolic, autoimmune, and paraneoplastic etiologies must be considered and 
explored. PNS are rare and often associated with antibodies against neural antigens expressed 
by the tumor. The case presented above describes a patient with a BRAF-positive malignant 
melanoma metastasis from an occult primary associated with PCD. The patient was success-
fully treated for the movement and neuropsychiatric symptoms with prednisone, azathio-
prine, olanzapine, and quetiapine, while the targeted treatment for metastasis from the 
malignant melanoma was with BRAF and MEK protein inhibitors.
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